YUQIN YIN^1,2,#, YU WU^1,#, HONGLIANG HUANG^1,2, YINGYING DUAN^1,2, ZHONGWEN YUAN^1,2, LIHUI CAO^1,2, JINJIN YING^1,2, YONGHENG ZHOU^3,*, SENLING FENG^1,2,*

Oncology Research, Vol.32, No.12, pp. 1891-1902, 2024, DOI:10.32604/or.2024.048778 - 13 November 2024

Abstract Background: Polymethoxylated flavones (PMFs) are compounds present in citrus peels and other Rutaceae plants, which exhibit diverse biological activities, including robust antitumor and antioxidant effects. However, the mechanism of PMFs in reversing drug resistance to colon cancer remains unknown. In the present study, we aimed to investigate the potential connection between the aerobic glycolysis-ROS-autophagy signaling axis and the reversal of PTX resistance in colon cancer by PMFs. Methods: MTT Cell viability assay and colony formation assay were used to investigate the effect of PMFs combined with PTX in reversing HCT8/T cell resistance ex vivo; the mRNA… More > Graphic Abstract

XIAOXIAO HE¹, XUEQING ZHOU², JINPENG ZHANG², MINGFEI ZHANG², DANHONG ZENG², HENG ZHANG¹, SHUCAI YANG^2,*

BIOCELL, Vol.48, No.9, pp. 1331-1341, 2024, DOI:10.32604/biocell.2024.052625 - 04 September 2024

Abstract Objectives: This investigation aimed to elucidate the inhibitory impact of apatinib on the multidrug resistance of liver cancer both in vivo and in vitro. Methods: To establish a Hep3B/5-Fu resistant cell line, 5-Fu concentrations were gradually increased in the culture media. Hep3B/5-Fu cells drug resistance and its alleviation by apatinib were confirmed via flow cytometry and Cell Counting Kit 8 (CCK8) test. Further, Nuclear factor kappa B (NF-κB) siRNA was transfected into Hep3B/5-Fu cells to assess alterations in the expression of multidrug resistance (MDR)-related genes and proteins. Nude mice were injected with Hep3B/5-Fu cells to establish subcutaneous… More >

KUN FENG^1,#, HAO PENG^2,#, QINGPENG LV¹, YEWEI ZHANG^1,*

Oncology Research, Vol.32, No.6, pp. 1063-1078, 2024, DOI:10.32604/or.2024.047078 - 23 May 2024

Abstract Hepatocellular carcinoma (HCC) is a malignancy known for its unfavorable prognosis. The dysregulation of the tumor microenvironment (TME) can affect the sensitivity to immunotherapy or chemotherapy, leading to treatment failure. The elucidation of PHLDA2’s involvement in HCC is imperative, and the clinical value of PHLDA2 is also underestimated. Here, bioinformatics analysis was performed in multiple cohorts to explore the phenotype and mechanism through which PHLDA2 may affect the progression of HCC. Then, the expression and function of PHLDA2 were examined via the qRT-PCR, Western Blot, and MTT assays. Our findings indicate a substantial upregulation of… More >

EFFAT ALEMZADEH¹, LEILA ALLAHQOLI², AFROOZ MAZIDIMORADI³, ESMAT ALEMZADEH^1,4, FAHIMEH GHASEMI^4,5, HAMID SALEHINIYA⁶, IBRAHIM ALKATOUT^7,*

Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

KEGANG JIA^1,#, YAWEI WANG^2,#, QI CAO^3,*, YOUYU WANG^1,*

Oncology Research, Vol.32, No.2, pp. 409-419, 2024, DOI:10.32604/or.2023.042863 - 28 December 2023

Abstract Background: Lung cancer is the most prevalent cancer diagnosis and the leading cause of cancer death worldwide. Therapeutic failure in lung cancer (LUAD) is heavily influenced by drug resistance. This challenge stems from the diverse cell populations within the tumor, each having unique genetic, epigenetic, and phenotypic profiles. Such variations lead to varied therapeutic responses, thereby contributing to tumor relapse and disease progression. Methods: The Genomics of Drug Sensitivity in Cancer (GDSC) database was used in this investigation to obtain the mRNA expression dataset, genomic mutation profile, and drug sensitivity information of NSCLS. Machine Learning… More >

JIE ZHAO^1,#, XUANTAO YANG^2,#, HAIXI ZHANG¹, XUEZHONG GU^1,*

Oncology Research, Vol.32, No.2, pp. 325-337, 2024, DOI:10.32604/or.2023.030770 - 28 December 2023

Abstract Multiple myeloma (MM) is a hematological tumor with high mortality and recurrence rate. Carfilzomib is a new-generation proteasome inhibitor that is used as the first-line therapy for MM. However, the development of drug resistance is a pervasive obstacle to treating MM. Therefore, elucidating the drug resistance mechanisms is conducive to the formulation of novel therapeutic therapies. To elucidate the mechanisms of carfilzomib resistance, we retrieved the GSE78069 microarray dataset containing carfilzomib-resistant LP-1 MM cells and parental MM cells. Differential gene expression analyses revealed major alterations in the major histocompatibility complex (MHC) and cell adhesion molecules.… More >

SAYAKA IMATSUJI^1,#, YUKIKO UJIE^1,#, HIROYUKI ODAKE¹, MASAYA IMOTO^1,2, SUSUMU ITOH³, ETSU TASHIRO^1,3,*

Oncology Research, Vol.32, No.1, pp. 139-150, 2024, DOI:10.32604/or.2023.030190 - 15 November 2023

Abstract Growing evidence suggests an association between epithelial-mesenchymal transition (EMT), a hallmark of tumor malignancy, and chemoresistance to a number of anti-cancer drugs. However, the mechanism of EMT induction in the process of acquiring anti-cancer drug resistance remains unclear. To address this issue, we obtained a number of cisplatin-resistant clones from LoVo cells and found that almost all of them lost cell-cell contacts. In these clones, the epithelial marker E-cadherin was downregulated, whereas the mesenchymal marker N-cadherin was upregulated. Moreover, the expression of EMT-related transcription factors, including Slug, was elevated. On the other hand, the upregulation More >

FANBIAO KONG^1,2,#, KUN WU^3,4,#, LIMING PANG^2,#, YULIANG HUANG^2,#, LEI LI³, JING XU², FEITONG LI², YAN QING², ZHONGYU WANG², XIURONG HUANG³, SHENG XU², XIAOGANG ZHONG², ZHOU ZHU², XIAOTONG WANG^3,*, JIANRONG YANG^5,*

Oncology Research, Vol.30, No.6, pp. 277-288, 2022, DOI:10.32604/or.2022.027301 - 09 February 2023

Abstract Introduction: Siva-1, as a pro-apoptotic protein, has been shown to induce extensive apoptosis in a number of different cell lines. In our previous study, we showed that overexpressed Siva-1 decreased the apoptosis of gastric cancer cells. So, we believe that it can also work as an anti-apoptotic protein. The present study aimed to determine the specific role of Siva-1 in anticancer drug resistance in gastric cancer in vivo and in vitro and preliminarily reveal the mechanism. Materials and Methods: A vincristine-resistant MKN-28/VCR gastric cancer cell line with stably downregulated Siva-1 was established. The effect of Siva-1 downregulation… More >

YONGKANG SHI, JUN MA, KE CHEN, BIN CHEN^*

Oncology Research, Vol.30, No.4, pp. 201-210, 2022, DOI:10.32604/or.2022.027584 - 31 January 2023

Abstract 5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for various cancers. However, the drug resistance developed by tumor cells hinders the therapeutic effect. Konjac glucomannan (KGM) is indicated to sensitize 5-FU-resistant hepatocellular carcinoma (HCC) cells to 5-FU. In our study, we found that KGM or 5-FU treatment alone did not affect the malignant cell behaviors and endoplasmic reticulum (ER) stress of 5-FU-resistant HCC cells or HepG2/5-FU and Bel-7402/5-FU cells, while cotreatment with KGM and 5-FU significantly facilitated HCC cell apoptosis and ER stress and suppressed cell proliferation potential and migration abilities. Moreover, we explored the… More >

SEMA MISIR^1,*, SERAP OZER YAMAN², NINA PETROVIĆ^3,4, CEREN SUMER⁵, CEYLAN HEPOKUR¹, YUKSEL ALIYAZICIOGLU²

Oncology Research, Vol.30, No.4, pp. 157-172, 2022, DOI:10.32604/or.2022.027547 - 31 January 2023

Abstract Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′,… More >